ĐÁNH GIÁ KẾT QUẢ ĐIỀU TRỊ VIÊM GAN VI RÚT C MẠN BẰNG THUỐC KHÁNG VI RÚT TRỰC TIẾP (DAAS) Ở BỆNH NHÂN HIV TẠI KHOA BỆNH NHIỆT ĐỚI BỆNH VIỆN ĐA KHOA TỈNH PHÚ THỌ

Abstract

Background: HIV/HCV co-infection is common and poses many challenges for patients and healthcare workers. We did this research to: Objective: To evaluate the results of treatment of chronic hepatitis C with direct antiretroviral drugs (DAAs) in HIV patients at the Department of Tropical Diseases, Phu Tho Provincial General Hospital. Subjects and methods: a descriptive study of 46 patients diagnosed with HIV/HCV co-infection, who were indicated for direct antiretroviral therapy (DAAs). Results: The study subjects were mainly in the age group 40 - <50, accounting for 63.0%. The mean age was 44.9 ± 5.8 years old. Men with 89%. 52.1% of patients have a habit of using a lot of alcohol. The route of HCV transmission were through injecting drugs, accounting for 86.9%. The serum AST level increased by >40, accounting for 68.1%. The patient's ALT level increased, accounting for 66%. The high serum GGT index with a level > 200 is 31.9%. There were 39.1% of patients with liver fibrosis level F4. The number of patients with the virus level 4-6 (log10 copies/ml) was the highest, accounting for 53.2%. 97.8% (45/46) of the patients had a sustained virological response after 12 weeks of treatment. The values of hemoglobin, white blood cells, platelets, creatinine, billirubin, and albumin did not have any difference after 12 weeks of treatment p> 0.05. The average value of AST, ALT, GGT, APRI, and Fib-4 index changed to the downtrend statistically significant with p < 0.05. Viral quantification value after 12 weeks of treatment has a significant change with statistical significance (p < 0.001). No serious adverse effects have been recorded. Conclusion: Initial evaluation of the good efficacy of direct antiretroviral drugs (DAAs) in the treatment of HCV infection in HIV patients. The sustained virological response was good after 12 weeks of treatment, and the liver enzyme index and liver fibrosis index were improved. No serious adverse effects have been recorded.